Aldactazide

Nephrotic Syndrome, Ascites, Hypokalemia + 14 more
Treatment
18 FDA approvals
20 Active Studies for Aldactazide

What is Aldactazide

SpironolactoneThe Generic name of this drug
Treatment SummarySpironolactone is a medication used to treat a range of medical conditions, including heart failure, high blood pressure, and nephrotic syndrome. It works by blocking certain hormones in the body, which helps regulate sodium and water levels in the body. It can also be used off-label to treat hirsutism, female pattern hair loss, adult acne, and as part of medical gender transition. Spironolactone was approved by the FDA in 1960.
Spironolactoneis the brand name
Aldactazide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Spironolactone
Spironolactone
1960
288

Approved as Treatment by the FDA

Spironolactone, also known as Spironolactone, is approved by the FDA for 18 uses such as Primary Hyperaldosteronism and Swollen feet or ankles .
Primary Hyperaldosteronism
Helps manage Primary Hyperaldosteronism
Swollen feet or ankles
Helps manage Edema
Ascites
Helps manage Ascites
Hypokalemia
chronic heart failure with reduced ejection fraction (NYHA Class IV)
Helps manage chronic heart failure with reduced ejection fraction (NYHA Class IV)
Cirrhosis of the Liver
Helps manage Cirrhosis of the Liver
idiopathic hyperaldosteronism
Helps manage idiopathic hyperaldosteronism
Congestive Heart Failure (CHF)
Helps manage Congestive Heart Failure (CHF)
Hypesthesia
Helps manage chronic heart failure with reduced ejection fraction (NYHA Class IV)
Edema
Helps manage Edema
Hypesthesia
Helps manage chronic heart failure with reduced ejection fraction (NYHA Class III)
Cirrhosis
Helps manage Cirrhosis of the Liver
Hyperaldosteronism
Helps manage Primary Hyperaldosteronism
Nephrotic Syndrome
Helps manage Nephrotic Syndrome
Congestive Heart Failure
Helps manage Congestive Heart Failure (CHF)
Hypertensive disease
Helps manage High Blood Pressure (Hypertension)
Ascites
Helps manage Ascites
Hyperaldosteronism
Helps manage idiopathic hyperaldosteronism

Effectiveness

How Aldactazide Affects PatientsSpironolactone is a drug that helps the body get rid of extra water and salt while still keeping potassium. It blocks the hormone receptors in the kidneys that control sodium and water levels, leading to higher levels of renin and aldosterone. This drug is similar to the female hormone progesterone, and can cause some progestogenic and antiandrogenic effects.
How Aldactazide works in the bodySpironolactone helps reduce water retention in the body and lower blood pressure. It does this by blocking channels that allow sodium and potassium to be exchanged in the kidneys, leading to increased sodium and water excretion and more potassium retained in the body.

When to interrupt dosage

The measure of Aldactazide is contingent upon the determined malady, including Hypesthesia, Congestive Heart Failure and Cirrhosis. The quantity of dosage fluctuates according to the method of delivery outlined in the table beneath.
Condition
Dosage
Administration
Nephrotic Syndrome
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Ascites
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hypokalemia
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Acne Vulgaris
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hyperaldosteronism
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hyperaldosteronism
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Swollen feet or ankles
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hypesthesia
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hypesthesia
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Congestive Heart Failure
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hirsutism
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hypertensive disease
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hyperaldosteronism
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Cirrhosis
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Edema
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
Hypertension
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension
inadequate response to other therapeutic measures
50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Suspension - Oral, Topical, Gel, Gel - Topical, Tablet, coated - Oral, Tablet, coated, Suspension

Warnings

Aldactazide has six contraindications, so it should not be employed in cases of the conditions given in the following table.Aldactazide Contraindications
Condition
Risk Level
Notes
Renal Insufficiency
Do Not Combine
Anuria
Do Not Combine
Acute Kidney Injury
Do Not Combine
Hyperkalemia
Do Not Combine
Pulse Frequency
Do Not Combine
Addison Disease
Do Not Combine
There are 20 known major drug interactions with Aldactazide.
Common Aldactazide Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Spironolactone.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Spironolactone.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Spironolactone.
Cyclosporine
Major
The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.
Dabrafenib
Major
The metabolism of Dabrafenib can be decreased when combined with Spironolactone.
Aldactazide Toxicity & Overdose RiskSymptoms of spironolactone overdose may include drowsiness, confusion, rash, nausea, vomiting, dizziness, or diarrhea. Treating an overdose may involve keeping the patient hydrated, maintaining electrolyte balance, and monitoring vital functions. The highest toxic dose in mice, rats, and rabbits has been found to be greater than 1g/kg. Spironolactone should not be taken during pregnancy as it has been linked to male fetus feminization in animal studies. Breastfeeding mothers should also avoid this drug as it can be passed through breast milk, though no long-term side effects have been studied. Animal studies
image of a doctor in a lab doing drug, clinical research

Aldactazide Novel Uses: Which Conditions Have a Clinical Trial Featuring Aldactazide?

165 active studies are currently being conducted to evaluate the potential of Aldactazide to alleviate Hypokalemia, Hirsutism and Nephrotic Syndrome.
Condition
Clinical Trials
Trial Phases
Hypesthesia
8 Actively Recruiting
Not Applicable, Phase 1
Cirrhosis
53 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Ascites
2 Actively Recruiting
Not Applicable, Phase 2
Nephrotic Syndrome
5 Actively Recruiting
Phase 2, Not Applicable, Phase 3
Hypertension
0 Actively Recruiting
Congestive Heart Failure
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Hirsutism
0 Actively Recruiting
Hypokalemia
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Hyperaldosteronism
0 Actively Recruiting
inadequate response to other therapeutic measures
0 Actively Recruiting
Hyperaldosteronism
0 Actively Recruiting
Hypertensive disease
28 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Swollen feet or ankles
5 Actively Recruiting
Phase 2, Not Applicable, Phase 4
Hypesthesia
6 Actively Recruiting
Not Applicable, Phase 1, Phase 4
Hyperaldosteronism
0 Actively Recruiting
Edema
0 Actively Recruiting

Aldactazide Reviews: What are patients saying about Aldactazide?

5Patient Review
7/7/2009
Aldactazide for High Blood Pressure
The tablets are a bit large, but they're easy to swallow.
4.3Patient Review
11/22/2017
Aldactazide for High Blood Pressure
I unfortunately experienced some intense breast pain while taking this medication.
4Patient Review
2/10/2013
Aldactazide for High Blood Pressure
I was on this medication for a couple years, but I started having stomach pains, dizziness, nausea, sugar elevation, and muscle and joint pain. So I stopped taking it without consulting my doctor first. After only one week off the meds, my joints are almost pain free!
3Patient Review
1/20/2011
Aldactazide for High Blood Pressure
I'm still testing this out to see if there are any negative side effects. So far, so good!
2.7Patient Review
2/24/2014
Aldactazide for High Blood Pressure
My blood pressure has gone down since taking this medication, but my blood sugar and weight have increased. I've been told that I need to lose weight as a result, and now I'm considered borderline diabetic.
2.3Patient Review
10/22/2007
Aldactazide for High Blood Pressure
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about aldactazide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why is Aldactazide a hazardous drug?

"Hydrochlorothiazide may cause low potassium and sodium levels. The risk of low potassium may be increased in patients with cirrhosis, excessive urination, or with the concurrent use of drugs that lower potassium levels."

Answered by AI

What is the drug Aldactazide used for?

"This product is used to treat high blood pressure (hypertension), heart failure, or extra fluid in the body (edema). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems."

Answered by AI

Can Aldactazide cause low potassium?

"If you have low potassium levels, you may experience leg cramps, constipation, irregular heartbeats, increased thirst or urination, numbness or tingling, muscle weakness, or a limp feeling."

Answered by AI

Is Aldactazide the same as spironolactone?

"Aldactazide is a diuretic that is used to treat heart failure, high blood pressure, and swelling due to certain liver or kidney problems. It is a 2-in-1 diuretic that combines two diuretics into a single pill for convenience."

Answered by AI

Clinical Trials for Aldactazide

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

AI-Enabled Identification for Fatty Liver Disease

18+
All Sexes
Los Angeles, CA
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical Center (+3 Sites)
Have you considered Aldactazide clinical trials? We made a collection of clinical trials featuring Aldactazide, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamPankaj Arora, MD, FAHA
Image of Cleveland Clinic Main Campus in Cleveland, United States.

Metabolic Surgery and TIPS for Liver Cirrhosis

18 - 70
All Sexes
Cleveland, OH
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present. This study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes. The study will compare two groups: 1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG). 2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications). All participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups. The main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment. Participants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes. This study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.
Phase 4
Recruiting
Cleveland Clinic Main CampusSobia Laique, MD
Image of NewYork-Presbyterian/Weill Cornell Medical Center in New York, United States.

Melatonin for Liver Cirrhosis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL? This is a pilot study, where participants will: * take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.
Recruiting
Has No Placebo
NewYork-Presbyterian/Weill Cornell Medical CenterAdam Buckholz, MD MS
Have you considered Aldactazide clinical trials? We made a collection of clinical trials featuring Aldactazide, we think they might fit your search criteria.Go to Trials
Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA
Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.
Waitlist Available
Has No Placebo
Virginia Commonwealth UniversityAarti Sarwal
Image of Future Life Clinical Trials in Miami, United States.

Extended vs Immediate Release Torsemide for Heart Failure

18+
All Sexes
Miami, FL
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. During the study period, participants' current loop diuretics will be replaced with an equivalent dose of either immediate-release or extended-release torsemide. Following a one-week stabilization period on the assigned torsemide formulation, patients will report to the clinical site for an assessment visit. On the study day, patients will take a single dose of the same torsemide formulation they have been on for the past week, administered after breakfast. Urine samples be collected are: * 0-4 hours post-dosing (pre-lunch period) * 4-8 hours post-dosing (post-lunch period) * 8-24 hours post-dosing (24 hours period) The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
Phase 4
Recruiting
Future Life Clinical TrialsSalim Shah, PhD, JDSarfez Pharmaceuticals, Inc.
Have you considered Aldactazide clinical trials? We made a collection of clinical trials featuring Aldactazide, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security